Sitagliptin and Dapagliflozin 100/10 | ST- Gliptin Dapa 100/10

Description

ST- Gliptin Dapa 100/10 Sitagliptin and Dapagliflozin 100/10 ST-GLIPTIN DAPA 100/10 is a modern oral antidiabetic medicine formulated with Sitagliptin Phosphate 100 mg and Dapagliflozin 10 mg. This powerful dual-drug combination is designed to provide effective glycaemic control in adults with Type 2 Diabetes Mellitus. By targeting blood glucose regulation through complementary mechanisms, ST-GLIPTIN DAPA 100/10 helps maintain stable blood sugar levels while reducing the risk of diabetes-related complications. This combination therapy is commonly prescribed when diet, exercise, or single-drug treatment alone does not provide adequate glucose control. ST-GLIPTIN DAPA 100/10 supports comprehensive diabetes management with added metabolic and cardiovascular benefits. Uses ST-GLIPTIN DAPA 100/10 is primarily used for: Management of Type 2 Diabetes Mellitus Improving glycaemic control when monotherapy is insufficient Reducing fasting and post-prandial blood glucose levels Adjunct therapy with diet and exercise for better diabetes control Patients requiring combination oral antidiabetic therapy This medicine is not indicated for Type 1 diabetes or diabetic ketoacidosis. Benefits 1. Dual Mechanism of Action Sitagliptin enhances insulin secretion and suppresses glucagon release, while Dapagliflozin promotes glucose excretion through urine, ensuring effective blood sugar reduction. 2. Effective Glycaemic Control Helps control both fasting and post-meal blood glucose levels, reducing HbA1c effectively. 3. Low Risk of Hypoglycaemia When used alone or without insulin or sulfonylureas, the risk of low blood sugar is minimal. 4. Weight-Neutral or Weight-Reducing Effect Dapagliflozin may aid in modest weight reduction by eliminating excess glucose calories. 5. Cardiovascular and Renal Benefits Dapagliflozin has shown benefits in reducing cardiovascular risk and supporting kidney health in diabetic patients. 6. Convenient Once-Daily Therapy Improves patient compliance with a simple and effective dosing regimen. Dosage The usual recommended dose of ST-GLIPTIN DAPA 100/10 is one tablet once daily, preferably taken at the same time each day. It may be taken with or without food, as advised by the physician. Dosage adjustments depend on kidney function, patient response, and concurrent medications. Important: Always follow your doctor’s instructions and do not alter the dose without medical advice. Side Effects Most patients tolerate ST-GLIPTIN DAPA 100/10 well. However, some may experience mild side effects such as: Headache Nausea Increased urination Urinary tract infection Genital fungal infections Nasopharyngitis Rare but Serious Side Effects Dehydration or low blood pressure Pancreatitis (rare) Kidney function changes Seek medical attention if you experience severe abdominal pain, persistent vomiting, or signs of infection. Precautions and Warning Kidney Disease: Dose adjustment or monitoring may be required. Elderly Patients: Monitor hydration status and kidney function. Pregnancy and Breastfeeding: Use only if clearly prescribed by a healthcare professional. Risk of Infections: Maintain good personal hygiene to reduce genital or urinary infections. Surgery or Severe Illness: Inform your doctor before continuing the medicine. Lifestyle Management: Continue a balanced diet, regular exercise, and blood sugar monitoring. Avoid alcohol excess, as it may increase the risk of dehydration or low blood sugar. Conclusion ST-GLIPTIN DAPA 100/10, containing Sitagliptin Phosphate 100 mg and Dapagliflozin 10 mg, is an effective and well-balanced oral therapy for managing Type 2 Diabetes Mellitus. Its dual-action approach ensures improved glycaemic control, reduced insulin resistance, and additional metabolic benefits. When used under medical supervision and combined with lifestyle modifications, ST-GLIPTIN DAPA 100/10 helps patients achieve better blood sugar stability, reduce long-term complications, and improve overall quality of life. It stands as a reliable choice in modern diabetes management.